NextPlat shares surge 11.14% intraday on expected 75% sequential 340B revenue growth from new initiatives and leadership expansion.

NextPlat surged 11.14% intraday after announcing new business initiatives in the second half of 2025 contributed to nearly 75% sequential quarterly growth in 340B contract revenue. The company highlighted expanded leadership involvement from Chairman Rodney Barreto, who secured two healthcare contracts earlier this year, and outlined plans to pursue joint ventures and acquisitions to scale its pharmacy services. Preliminary data from October to December 2025 indicated over 12,000 additional 340B and contracted prescriptions, signaling strong momentum in its healthcare division. The strategic focus on growth and Barreto’s enhanced role, coupled with forward-looking revenue guidance, drove immediate investor optimism, overshadowing a prior Q3 earnings report that noted revenue declines. The stock’s sharp intraday rise reflects confidence in the company’s refocused strategy and projected sequential improvements.